All In Biotech

Drug Trial Radar · NCT05462756

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Aug 11, 2022

Primary completion

Feb 27, 2024

Study completion Feb 27, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.

Conditions

  • Type 2 Diabetes
  • Type 2 Diabetes Treated With Insulin

Interventions

  • Insulin Efsitora AlfaDrug

    Administered SC

  • Insulin Lispro (U100)Drug

    Administered SC

  • Insulin Glargine (U100)Drug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]Time frame: Baseline, Week 26

Locations

81 sites in 8 countries. Site status is shown where the registry gives one.

  • CMR of Greater New Haven, LLC

    Hamden, Connecticut

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • Encore Medical Research - Weston

    Weston, Florida

  • Elite Clinical Trials

    Blackfoot, Idaho

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho

  • MedStar Good Samaritan Hospital

    Baltimore, Maryland

  • NECCR PrimaCare Research

    Fall River, Massachusetts

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan

  • Palm Research Center Tenaya

    Las Vegas, Nevada

  • Palm Research Center Sunset

    Las Vegas, Nevada

  • Research Foundation of SUNY - University of Buffalo

    Buffalo, New York

  • Remington Davis Clinical Research

    Columbus, Ohio

  • Aventiv Research

    Dublin, Ohio

  • Heritage Valley Multispecialty Group, Inc

    Beaver, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas

  • North Texas Endocrine Center

    Dallas, Texas

  • Biopharma Informatic, LLC

    Houston, Texas

  • Research Institute of Dallas

    Plano, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • Chrysalis Clinical Research

    St. George, Utah

  • Rainier Clinical Research Center

    Renton, Washington

  • CENUDIAB

    Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Córdoba

    Córdoba, Argentina

  • Centro de Investigaciones Clinicas del Litoral

    Santa Fe, Argentina

  • Consultorio de Investigación Clínica EMO SRL

    Ciudad Autonoma de Buenos Aire, Buenos Air, Argentina

  • CEDIC

    CABA, Buenos Aires, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina

  • Go Centro Medico San Nicolás

    San Nicolás de los Arroyos, Buenos Aires, Argentina

  • Mautalen Salud e Investigación

    Buenos Aires, Buenos Aires F.D., Argentina

  • CIPREC

    CABA, Buenos Aires F.D., Argentina

  • Instituto Centenario

    CABA, Ciudad Autónoma de Buenos Aire, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aire, Argentina

  • Instituto Médico Río Cuarto

    Río Cuarto, Córdoba Province, Argentina

  • Centro de Salud e Investigaciones Médicas

    Santa Rosa, La Pampa Province, Argentina

  • Instituto de Investigaciones Clinicas Rosario-Sanatorio Delta

    Rosario, Santa Fe Province, Argentina

  • Instituto Médico Catamarca IMEC

    Rosario, Santa Fe Province, Argentina

  • Centro de Investigaciones Médicas Tucuman

    San Miguel de Tucumán, Tucumán Province, Argentina

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.